| Date |
Speakers(s) |
Program
Topic |
 |
| January
2009 |
Harold Van Wart, PhD
President
& CEO
Metabolex |
Next Generation
Therapy for Diabetes |
| February
2009 |
Anthony Allison, MD, PhD
Vice
President, Research
Alavita
Pharmaceuticals, Inc. |
Improving Organ
Transplantation |
| March
2009 |
Paul Sekhri
Head, Biotech
Operations Group
TPG
Biotech |
Extraordinary Times
Call for Extraordinary Measures: One Venture Capitalist’s Perspective |
| April
2009 |
Mike Varney, PhD
Senior Vice President
Small Molecule Group
Genentech |
What is the State of the Art of Small Molecule Drug Discovery? |
| May
2009 |
Lynn Seely, MD
Chief Medical Officer
Medivation |
Developing a Novel Drug for Alzheimer’s Disease: Unique Challenges and Opportunities |
| June
2009 |
Harris Kaplan
Founder, CEO
Healogix, LLC |
Crossing the Biotech-Pharma Chasm |
| July
2009 |
Stephen Harrison, PhD
SVP, Research
Kai Pharmaceuticals |
Clinically Validated Inhibitors of Intracellular Protein Interactions |
| August
2009 |
Judith Campisi, PhD
Professor
Lawrenece Livermore National Laboratory |
Curing Aging, A Mad Pursuit? |
| September
2009 |
Wendye Robbins, MD
President & CEO
Limerick BioPharma |
Turning the Paradigm Inside Out: Stimulating ABC Family Transporters to Protect Cells Against Disease and Drug Toxicity |
| October
2009 |
Stephen Quake, PhD
Professor
Stanford University |
Precision Measurements in Biology |
| November
2009 |
Hans Reiser, MD
Vice President, BIology
Gilead Sciences, Inc. |
Infectious Diseases Research in the 21st Century |
| December
2009 |
Jake Plattner, PhD
Senior Vice President, Research
Anacor |
The Discovery of Novel Boron-containing Antimicrobial Agents |
